Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Evolva Holding

SWX:EVE
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EVE
SWX
CHF137M
Market Cap
  1. Home
  2. CH
  3. Materials
Company description

Evolva Holding SA discovers, develops, and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, the United States, and internationally. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Evolva Holding has significant price volatility in the past 3 months.
EVE Share Price and Events
7 Day Returns
-4.7%
SWX:EVE
-0.8%
CH Chemicals
1.4%
CH Market
1 Year Returns
-26.2%
SWX:EVE
6.2%
CH Chemicals
-5.2%
CH Market
EVE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Evolva Holding (EVE) -4.7% -24.4% -20.2% -26.2% -70.9% -89.5%
CH Chemicals -0.8% -10.3% -10.8% 6.2% 24.5% 38.9%
CH Market 1.4% -9% -13.7% -5.2% 3.7% -2.6%
1 Year Return vs Industry and Market
  • EVE underperformed the Chemicals industry which returned 6.2% over the past year.
  • EVE underperformed the Market in Switzerland which returned -5.2% over the past year.
Price Volatility
EVE
Industry
5yr Volatility vs Market

EVE Value

 Is Evolva Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Evolva Holding to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Evolva Holding.

SWX:EVE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 4.3%
Perpetual Growth Rate 10-Year CH Government Bond Rate -0.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:EVE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate -0.6%
Equity Risk Premium S&P Global 5.4%
Chemicals Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.807 (1 + (1- 18%) (4.46%))
0.89
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.89
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.55% + (0.89 * 5.44%)
4.29%

Discounted Cash Flow Calculation for SWX:EVE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Evolva Holding is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:EVE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CHF, Millions) Source Present Value
Discounted (@ 4.29%)
2020 -11.00 Analyst x1 -10.55
2021 -7.00 Analyst x1 -6.44
2022 1.00 Analyst x1 0.88
2023 1.50 Est @ 50.41% 1.27
2024 2.03 Est @ 35.12% 1.65
2025 2.53 Est @ 24.42% 1.97
2026 2.96 Est @ 16.93% 2.20
2027 3.30 Est @ 11.69% 2.36
2028 3.57 Est @ 8.02% 2.44
2029 3.76 Est @ 5.45% 2.47
Present value of next 10 years cash flows CHF-1.00
SWX:EVE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CHF3.76 × (1 + -0.55%) ÷ (4.29% – -0.55%)
CHF77.23
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CHF77.23 ÷ (1 + 4.29%)10
CHF50.73
SWX:EVE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CHF-1.00 + CHF50.73
CHF49.73
Equity Value per Share
(CHF)
= Total value / Shares Outstanding
= CHF49.73 / 800.34
CHF0.06
SWX:EVE Discount to Share Price
Calculation Result
Value per share (CHF) From above. CHF0.06
Current discount Discount to share price of CHF0.17
= -1 x (CHF0.17 - CHF0.06) / CHF0.06
-176.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Evolva Holding is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Evolva Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Evolva Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:EVE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CHF CHF-0.03
SWX:EVE Share Price ** SWX (2020-04-03) in CHF CHF0.17
Switzerland Chemicals Industry PE Ratio Median Figure of 5 Publicly-Listed Chemicals Companies 26.13x
Switzerland Market PE Ratio Median Figure of 175 Publicly-Listed Companies 16.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Evolva Holding.

SWX:EVE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:EVE Share Price ÷ EPS (both in CHF)

= 0.17 ÷ -0.03

-6.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evolva Holding is loss making, we can't compare its value to the CH Chemicals industry average.
  • Evolva Holding is loss making, we can't compare the value of its earnings to the Switzerland market.
Price based on expected Growth
Does Evolva Holding's expected growth come at a high price?
Raw Data
SWX:EVE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.11x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
26.1%per year
Europe Chemicals Industry PEG Ratio Median Figure of 59 Publicly-Listed Chemicals Companies 1.2x
Switzerland Market PEG Ratio Median Figure of 125 Publicly-Listed Companies 1.81x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Evolva Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Evolva Holding's assets?
Raw Data
SWX:EVE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CHF CHF0.22
SWX:EVE Share Price * SWX (2020-04-03) in CHF CHF0.17
Switzerland Chemicals Industry PB Ratio Median Figure of 7 Publicly-Listed Chemicals Companies 3.67x
Switzerland Market PB Ratio Median Figure of 216 Publicly-Listed Companies 1.33x
SWX:EVE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:EVE Share Price ÷ Book Value per Share (both in CHF)

= 0.17 ÷ 0.22

0.77x

* Primary Listing of Evolva Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evolva Holding is good value based on assets compared to the CH Chemicals industry average.
X
Value checks
We assess Evolva Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
  5. Evolva Holding has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EVE Future Performance

 How is Evolva Holding expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Evolva Holding expected to grow at an attractive rate?
  • Unable to compare Evolva Holding's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Evolva Holding's earnings growth to the Switzerland market average as it is expected to be loss making during the next 1-3 years.
  • Evolva Holding's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:EVE Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:EVE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 26.1%
SWX:EVE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 34%
Switzerland Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 11.1%
Switzerland Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 4.9%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 8.3%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 2.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:EVE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:EVE Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 73 1
2023-12-31 56 1
2022-12-31 36 0 -9 2
2021-12-31 24 -8 -15 2
2020-12-31 11 -12 -19 1
2020-04-03
SWX:EVE Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2019-12-31 12 -14 -22
2019-09-30 12 -16 -23
2019-06-30 11 -18 -25
2019-03-31 10 -21 -27
2018-12-31 9 -24 -29
2018-09-30 8 -29 -31
2018-06-30 7 -34 -33
2018-03-31 7 -35 -36
2017-12-31 7 -36 -39
2017-09-30 8 -35 -38
2017-06-30 10 -34 -37
2017-03-31 10 -34 -37

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Evolva Holding is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Evolva Holding's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:EVE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Evolva Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:EVE Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31 0.00 0.00 0.00 1.00
2022-12-31 -0.01 -0.01 -0.01 2.00
2021-12-31 -0.02 -0.02 -0.02 2.00
2020-12-31 -0.02 -0.02 -0.02 1.00
2020-04-03
SWX:EVE Past Financials Data
Date (Data in CHF Millions) EPS *
2019-12-31 -0.03
2019-09-30 -0.03
2019-06-30 -0.03
2019-03-31 -0.03
2018-12-31 -0.04
2018-09-30 -0.04
2018-06-30 -0.05
2018-03-31 -0.06
2017-12-31 -0.08
2017-09-30 -0.09
2017-06-30 -0.09
2017-03-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Evolva Holding will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Evolva Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Evolva Holding has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EVE Past Performance

  How has Evolva Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Evolva Holding's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Evolva Holding does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Evolva Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Evolva Holding's 1-year growth to the CH Chemicals industry average as it is not currently profitable.
Earnings and Revenue History
Evolva Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Evolva Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:EVE Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 11.60 -21.64 11.68 13.74
2019-09-30 11.54 -23.24 12.36 14.83
2019-06-30 11.49 -24.84 13.04 15.92
2019-03-31 10.21 -27.03 13.66 17.25
2018-12-31 8.93 -29.21 14.27 18.59
2018-09-30 7.98 -31.27 15.59 28.26
2018-06-30 7.04 -33.32 16.90 37.94
2018-03-31 6.94 -36.15 17.88 33.07
2017-12-31 6.85 -38.98 18.85 28.20
2017-09-30 8.18 -38.23 17.70 14.10
2017-06-30 9.52 -37.48 16.55
2017-03-31 9.55 -36.73 15.66
2016-12-31 9.58 -35.97 14.77
2016-09-30 9.17 -34.82 14.07
2016-06-30 8.77 -33.67 13.37
2016-03-31 11.07 -32.78 12.92
2015-12-31 13.36 -31.89 12.46
2015-09-30 13.70 -29.99 11.89
2015-06-30 14.03 -28.08 11.31
2015-03-31 12.39 -24.72 10.33
2014-12-31 10.74 -21.35 9.35
2014-09-30 10.23 -19.49 8.87
2014-06-30 9.72 -17.63 8.39
2014-03-31 9.21 -16.68 7.96
2013-12-31 8.71 -15.73 7.52
2013-09-30 8.09 -14.93 6.90
2013-06-30 7.48 -14.12 6.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Evolva Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Evolva Holding has efficiently used its assets last year compared to the CH Chemicals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Evolva Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Evolva Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Evolva Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EVE Health

 How is Evolva Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Evolva Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Evolva Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Evolva Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Evolva Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.4881765779062E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Evolva Holding Company Filings, last reported 3 months ago.

SWX:EVE Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 172.56 0.00 39.92
2019-09-30 172.56 0.00 39.92
2019-06-30 183.29 0.00 45.34
2019-03-31 183.29 0.00 45.34
2018-12-31 194.16 0.00 60.38
2018-09-30 194.16 0.00 60.38
2018-06-30 208.24 0.00 74.97
2018-03-31 208.24 0.00 74.97
2017-12-31 220.72 0.00 97.18
2017-09-30 220.72 0.00 97.18
2017-06-30 151.90 0.00 33.83
2017-03-31 151.90 0.00 33.83
2016-12-31 173.06 0.00 47.52
2016-09-30 173.06 0.00 47.52
2016-06-30 184.65 0.00 66.72
2016-03-31 184.65 0.00 66.72
2015-12-31 203.42 0.00 83.23
2015-09-30 203.42 0.00 83.23
2015-06-30 156.69 3.46 47.42
2015-03-31 156.69 3.46 47.42
2014-12-31 174.99 3.52 60.71
2014-09-30 174.99 3.52 60.71
2014-06-30 115.88 3.59 61.00
2014-03-31 115.88 3.59 61.00
2013-12-31 83.28 3.65 29.29
2013-09-30 83.28 3.65 29.29
2013-06-30 88.40 4.70 31.79
  • Evolva Holding's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (2% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Evolva Holding has sufficient cash runway for 2 years based on current free cash flow.
  • Unable to confirm if Evolva Holding has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Evolva Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Evolva Holding has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EVE Dividends

 What is Evolva Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Evolva Holding dividends.
If you bought CHF2,000 of Evolva Holding shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Evolva Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Evolva Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:EVE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Switzerland Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.3%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 159 Stocks 3.3%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Switzerland Bottom 25% Dividend Yield 25th Percentile 2.1%
Switzerland Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:EVE Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Evolva Holding has not reported any payouts.
  • Unable to verify if Evolva Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Evolva Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Evolva Holding has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Evolva Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Evolva Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Evolva Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EVE Management

 What is the CEO of Evolva Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Oliver Walker
COMPENSATION CHF914,200
AGE 50
TENURE AS CEO 1.8 years
CEO Bio

Mr. Oliver Walker has been Chief Executive Officer of Evolva Holding SA since July 10, 2018. Mr. Walker serves as Director of Kuros Biosciences AG since June 14, 2018. He served as the Chief Financial Officer of Evolva Holding SA since December 1, 2016 until July 2018. Mr. Walker is Finance Executive and has more than 20 years of experience in international companies, both listed and privately held, and was active in high growth industries and mature industries alike. His experience covers all aspects of finance including M&A, capital market transactions, treasury, reporting and fundraising. He served as Chief Financial Officer of Sivantos Group at Auris Luxembourg II S.A. since March 2015 until October 2015. Mr. Walker served as Chief Financial Officer at Sivantos Pte. Ltd. since February 13, 2015 until January 29, 2016. Mr. Walker served as the Chief Financial Officer of Nobel Biocare Holding AG from August 1, 2012 to February 1, 2015 and served its Executive Vice President until February 1, 2015. Mr. Walker has an extensive financial and operational expertise including retail management, restructuring as well as mergers and acquisitions. He served as the Chief Financial Officer of Sonova Holding AG. (Formerly known as Phonak Holding AG.) from October 1, 2004 to March 30, 2011 and its Member of the Management Board until March 30, 2011. Mr. Walker served as the Chief Financial Officer of Stratec Medical Group of Oberdorf, Switzerland from 2000 to 2004. Prior to Stratec, Mr. Walker served seven years at the Von Roll Group, where he served as the Head of Finance and Controlling for the Division Von Roll Infratec. He obtained Master of Science in Business Administration and Economics from the University of Berne.

CEO Compensation
  • Oliver's compensation has increased whilst company is loss making.
  • Oliver's remuneration is higher than average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Evolva Holding management team in years:

1.8
Average Tenure
55
Average Age
  • The average tenure for the Evolva Holding management team is less than 2 years, this suggests a new team.
Management Team

Oliver Walker

TITLE
Chief Executive Officer
COMPENSATION
CHF914K
AGE
50
TENURE
1.8 yrs

Jutta Heim

TITLE
Scientific Consultant & Director
COMPENSATION
CHF80K
AGE
68

André Pennartz

TITLE
Chief Financial Officer
TENURE
0.3 yrs

Scott Fabro

TITLE
COO & Chief Commercial Officer
AGE
55
TENURE
1.8 yrs

Barbara Duci

TITLE
Head of Investor & Corporate Relations

Simon Waddington

TITLE
COO of Products
AGE
55

Luc Gruner

TITLE
Executive Officer
AGE
67
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Evolva Holding board of directors in years:

7.9
Average Tenure
64.5
Average Age
  • The tenure for the Evolva Holding board of directors is about average.
Board of Directors

Gerard Hoetmer

TITLE
Chairman
COMPENSATION
CHF160K
AGE
63
TENURE
2.9 yrs

Jutta Heim

TITLE
Scientific Consultant & Director
COMPENSATION
CHF80K
AGE
68
TENURE
6.9 yrs

Martin Gertsch

TITLE
Director
COMPENSATION
CHF95K
AGE
54
TENURE
7.9 yrs

Thomas Videbaek

TITLE
Director
COMPENSATION
CHF88K
AGE
59
TENURE
7.9 yrs

Karsten Kristiansen

TITLE
Member of Scientific Advisory Board
AGE
69

Karl-Heinz Altmann

TITLE
Member of Scientific Advisory Board

Jay Keasling

TITLE
Member of Scientific Advisory Board

Kish Kishore

TITLE
Director
COMPENSATION
CHF80K
AGE
66
TENURE
8.9 yrs

Birger Møller

TITLE
Member of Scientific Advisory Board

Vincent Martin

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Evolva Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Evolva Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EVE News

Simply Wall St News

Evolva Holding SA (VTX:EVE): Poised For Long-Term Success?

In February 2019, Evolva Holding SA (VTX:EVE) announced its most recent earnings update, which indicated company earnings became less negative compared to the previous year's level - great news for investors Today I want to provide a brief commentary on how market analysts perceive Evolva Holding's earnings growth outlook over the next couple of years and whether the future looks brighter. … Check out our latest analysis for Evolva Holding Market analysts' consensus outlook for the upcoming year seems buoyant, with earnings becoming less negative, arriving at -CHF20.8m in 2020. … SWX:EVE Past and Future Earnings, August 21st 2019 Even though it is helpful to be aware of the growth each year relative to today’s value, it may be more beneficial to gauge the rate at which the earnings are growing every year, on average.

Simply Wall St -

What's The Cash Runway For Evolva Holding SA (VTX:EVE)?

Currently, Evolva Holding has CHF60m in cash holdings and producing negative free cash flow of -CHF36.5m. … The riskiest factor facing investors of Evolva Holding is the potential for the company to run out of cash without the ability to raise more money. … SWX:EVE Income Statement, July 3rd 2019 When will Evolva Holding need to raise more cash?

Simply Wall St -

Did Changing Sentiment Drive Evolva Holding's (VTX:EVE) Share Price Down A Painful 86%?

Spare a thought for those who held Evolva Holding SA (VTX:EVE) for five whole years - as the share price tanked 86%. … View our latest analysis for Evolva Holding Evolva Holding isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Over half a decade Evolva Holding reduced its trailing twelve month revenue by 7.3% for each year.

Simply Wall St -

Are Investors Undervaluing Evolva Holding SA (VTX:EVE) By 47%?

How far off is Evolva Holding SA (VTX:EVE) from its intrinsic value? … by taking the foreast future cash flows of the company and discounting them back to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

What You Must Know About Evolva Holding SA's (VTX:EVE) Beta Value

If you're interested in Evolva Holding SA (VTX:EVE), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

Should You Care About Evolva Holding SA’s (VTX:EVE) Cash Levels?

If you are currently a shareholder in Evolva Holding SA (VTX:EVE), or considering investing in the stock, you need to examine how the business generates cash, and how it is reinvested. … I’ve analysed below, the health and outlook of Evolva Holding’s cash flow, which will help you understand the stock from a cash standpoint. … Evolva Holding generates cash through its day-to-day business, which needs to be reinvested into the company in order for it to continue operating.

Simply Wall St -

Does Evolva Holding SA (VTX:EVE) Have Enough Money Left To Grow?

Cash is crucial to run a business, and if a company burns through its reserves fast, it will need to raise further funds. … With a negative free cash flow of -CHF36.5m, Evolva Holding is chipping away at its CHF60m cash reserves in order to run its business … The riskiest factor facing investors of Evolva Holding is the potential for the company to run out of cash without the ability to raise more money.

Simply Wall St -

Easy Come, Easy Go: How Evolva Holding Shareholders Got Unlucky And Saw 87% Of Their Cash Evaporate

For example, we sympathize with anyone who was caught holding Evolva Holding SA (VTX:EVE) during the five years that saw its share price drop a whopping 87%. … Evolva Holding isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … The share price fall of 33% (per year, over five years) is a stern reminder that money-losing companies are expected to grow revenue.

Simply Wall St -

Do Directors Own Evolva Holding SA (VTX:EVE) Shares?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that used to be publicly owned tend to have lower insider ownership. … Evolva Holding is a smaller company with a market capitalization of CHF162m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Should You Investigate Evolva Holding SA (VTX:EVE) At CHF0.22?

saw significant share price movement during recent months on the SWX, rising to highs of CHF0.29 and falling to the lows of CHF0.21. … Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price? … A question to answer is whether Evolva Holding's current trading price of CHF0.22 reflective of the actual value of the?

Simply Wall St -

EVE Company Info

Description

Evolva Holding SA discovers, develops, and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, the United States, and internationally. It offers branded ingredients, such as Veri-te Resveratrol, a natural ingredient in grapes, as well as other plants, including peanuts, cranberries, and Japanese knotweed for use in age-related health conditions; Nootkashield for pest control applications; EverSweet Stevia, a sweetener use in food, beverages, and table-top sweeteners; EveNootkatone, an ingredient for flavour and fragrance applications; and EveValencene, a citrus flavor. The company also develops and sells own products. It serves the nutrition, flavors and fragrances, animal health, personal care, and pharmaceutical markets. The company was founded in 2004 and is headquartered in Reinach, Switzerla.

Details
Name: Evolva Holding SA
EVE
Exchange: SWX
Founded: 2004
CHF137,338,107
800,338,621
Website: http://www.evolva.com
Address: Evolva Holding SA
Duggingerstrasse 23,
Reinach,
Basel-Landschaft, 4153,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX EVE Common Shares SIX Swiss Exchange CH CHF 11. Sep 2009
OTCPK ELVA.F Common Shares Pink Sheets LLC US USD 11. Sep 2009
DB ADF Common Shares Deutsche Boerse AG DE EUR 11. Sep 2009
LSE 0QQJ Common Shares London Stock Exchange GB CHF 11. Sep 2009
OTCPK ELVA.Y SPONSORED ADR Pink Sheets LLC US USD 04. Feb 2014
Number of employees
Current staff
Staff numbers
66
Evolva Holding employees.
Industry
Specialty Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 22:55
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.